ImageneBio, Inc. Total Liabilities
ImageneBio, Inc. total liabilities. Based on the latest financial reports, ImageneBio, Inc. (IMA) has total liabilities worth $9.97 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IMA financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ImageneBio, Inc. (2018–2025)
Total liabilities of ImageneBio, Inc. from 2018 to 2025. This chart illustrates how ImageneBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore IMA long-term investments to assets to see how much of total assets are deployed in long-term investments.
ImageneBio, Inc. Competitors by Total Liabilities
The table below lists competitors of ImageneBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hyundai Industrial Co. Ltd
KQ:170030
|
Korea | ₩82.12 Billion |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
USA | $39.23 Million |
|
I-Hwa Industrial Co Ltd
TW:1456
|
Taiwan | NT$11.68 Billion |
|
Deswell Industries Inc
NASDAQ:DSWL
|
USA | $20.57 Million |
|
PS Tec. Co. Ltd
KQ:002230
|
Korea | ₩38.95 Billion |
|
Fission 3.0 Corp
V:FUU
|
Canada | CA$24.70 Million |
|
The LEADCORP Inc
KQ:012700
|
Korea | ₩595.00 Billion |
|
Centara Hotels & Resorts Leasehold Property Fund
BK:CTARAF
|
Thailand | ฿900.00K |
Liability Composition Analysis (2018–2025)
This chart breaks down ImageneBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ImageneBio, Inc. balance sheet assets.
Liquidity & Leverage Metrics
ImageneBio, Inc. Total Liabilities Ratios Explained
ImageneBio, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ImageneBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ImageneBio, Inc. (2018–2025)
The table below shows the annual total liabilities of ImageneBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.84 Million | +27.36% |
| 2024-12-31 | $15.58 Million | -30.26% |
| 2023-12-31 | $22.34 Million | -11.68% |
| 2022-12-31 | $25.29 Million | -36.78% |
| 2021-12-31 | $40.00 Million | -85.15% |
| 2020-12-31 | $269.45 Million | +82.76% |
| 2019-12-31 | $147.44 Million | +121.66% |
| 2018-12-31 | $66.52 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more